ReviewFrontiers in immunology2026
The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large B-cell lymphoma is an aggressive lymphoma subtype with poor outcomes in the relapsed and refractory setting. Despite considerable improvements in long-term survival with CD19 CAR-T immunotherapy, over half of patients do not achieve durable remissions. A deeper understanding of the mechanisms within the tumor microenvironment that drive treatment resistance is critical to informing the development of improved CAR-T therapies that can overcome immunosuppressive elements. In this review, we synthesize current knowledge on how histological, cellular, molecular and spatial features of the large B-cell lymphoma microenvironment influence clinical responses following CD19 CAR-T therapy and highlight key knowledge gaps in the field. We discuss data from clinical trials of emerging novel CAR-T engineering strategies aimed at reprogramming the immunosuppressive tumor microenvironment and underscore the growing need for advanced analytical approaches capable of integrating multimodal, high-dimensional datasets to comprehensively characterize this complex tumor ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.